Identifizierung, Strukturableitung und Synthese bisher unbekannter Urofuransäuren im menschlichen Blut

Pfordt, J.; Thoma, Heinz; Spiteller, Gerhard

doi:10.1002/jlac.198119811217

Cited by 39 publications

(12 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Structually related substances designated as urofuranic acids. 3-carboxy-4-methyl-5-pentyl-2-furanpropanoic acid, 3-carboxy-4-methyl-5-(l-oxopropyl)-2-furanpropanoic acid and 3-carboxy-4-methyl-5-(l-hydroxypropyl)-2-furanpropanoic acid, have also been detected in both urineandserum obtained from healthy subjects [16,17,21,22]. Liebich et al [23] have recently reported the increased concentration of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in plasma from patients with chronic renal failure by using gas chromatography-mass spec trometry.…”

Section: Discussionmentioning

confidence: 99%

Isolation and Characterization of an Endogenous Drug-Binding Inhibitor Present in Uremic Serum

Mabuchi

Nakahashi²

1986

Nephron

View full text Add to dashboard Cite

Isolation of an endogenous ligand solute from uremic serum was performed by high-performance liquid chromatography. This ligand solute inhibited the binding of diphenylhydantoin and tryptophan to plasma protein, and was considered to be one of the endogenous drug-binding inhibitors present in uremic serum. The gas chromatographic-mass spectrometric analysis revealed that this inhibitor is 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, which is known to be a constituent of urine.

show abstract

Section: Discussionmentioning

confidence: 99%

Isolation and Characterization of an Endogenous Drug-Binding Inhibitor Present in Uremic Serum

Mabuchi

Nakahashi²

1986

Nephron

View full text Add to dashboard Cite

show abstract

“…3-Carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) was chemically synthesized. 10) Organic solvents used for CsA determination in biological fluids were of HPLC grade. All other chemicals were of reagent grade and used without further purification.…”

Section: Chemicalsmentioning

confidence: 99%

Evaluation of Factors to Decrease Bioavailability of Cyclosporin A in Rats with Gentamicin-Induced Acute Renal Failure

Shibata¹,

Inoue²,

Fukumoto³

et al. 2004

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

Focusing on the disposition of cyclosporin A (CsA) in the liver and intestine, effects of gentamicin-induced acute renal failure (ARF) on the decreased oral bioavailability of CsA were evaluated in rats. The area under the CsA concentration-time curve (AUC) in ARF rats after oral administration (5 mg/kg) significantly decreased by 43% as compared to the control, while the apparent oral clearance significantly increased by 76% of the control. The portal AUC of CsA in ARF rats with bile flow decreased by 67% as compared to the control rats. Without bile flow, the portal AUC of CsA in control rats decreased by 50% as compared to those with bile flow, whereas ARF rats without bile flow showed no notable change as compared to those with bile flow. The AUC of CsA mono-oxidative metabolite via CYP3A (M-OH) in ARF rats after oral or intravenous administration increased significantly by 84% or 241%, respectively, while there was no difference in the portal M-OH between control and ARF rats, suggesting that the elimination of M-OH was prolonged because of nephrotoxicity. Although the exsorption clearance of CsA from the blood circulation to the intestine after intravenous administration to ARF rats decreased significantly as compared to the control; and basolateral-to-apical transport of CsA through Caco-2 monolayers was significantly retarded in the presence of uremic toxins, there was no significant change in the total body clearance of CsA between ARF and control rats. Moreover, there were no effects of uremic toxins on the protein binding of CsA in plasma. These observations suggest that hepatic or intestinal CYP3A and P-glycoproteine (P-gp) are not likely to be concerned with lowering the oral bioavailability of CsA, and that bile function under the ARF condition induced by gentamicin is responsible for a marked decrease in the fraction absorbed of CsA in the small intestine.

show abstract

“…CMPF is a trace constituent of urine and blood of healthy subjects [1,4]. Furanoid fatty acids with similar chemical structures were first found in the livers and testes of several fish species as constituents of lipids [5,6], but the source and metabolism of CMPF remain unknown.…”

Section: Introductionmentioning

confidence: 99%

A Major Endogenous Ligand Substance Involved in Renal Failure

Mabuchi¹,

Nakahashi²

1988

Nephron

View full text Add to dashboard Cite

The clinical significance of a major endogenous ligand substance, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), present in the sera of patients with renal failure, was examined. In patients with chronic renal failure, the serum CMPF concentration was correlated with the serum creatinine concentration, but not in patients with acute renal failure. The accumulation of CMPF in the sera of patients with chronic renal failure may reflect the ‘chronicity’ of renal failure. Plasma exchange was more effective than direct hemoperfusion for the elimination of CMPF retained in uremic serum.

show abstract

Identifizierung, Strukturableitung und Synthese bisher unbekannter Urofuransäuren im menschlichen Blut

Cited by 39 publications

References 10 publications

Isolation and Characterization of an Endogenous Drug-Binding Inhibitor Present in Uremic Serum

Isolation and Characterization of an Endogenous Drug-Binding Inhibitor Present in Uremic Serum

Evaluation of Factors to Decrease Bioavailability of Cyclosporin A in Rats with Gentamicin-Induced Acute Renal Failure

A Major Endogenous Ligand Substance Involved in Renal Failure

Contact Info

Product

Resources

About